1. Assaying for antiviral activity of the folkloric medicinal desert plant Rhazya stricta on coronavirus SARS-CoV-2.
- Author
-
Baeshen, Mohammed N., Attar, Roba, Bouback, Thamer A., Albeshri, Abdulaziz O., Baeshen, Naseebh N., Karkashan, Alaa, Abbas, Basma, Aljaddawi, Abdullah A., Almulaiky, Yaaser Q., Mahmoud, Sara H., Abo Shama, Noura M., Ali, Mohamed A., Baadhaim, Moayad, Zakri, Samer, Alsayegh, Khaled, Mohammed, Arif, and Baeshen, Nabih A.
- Subjects
ANTIVIRAL agents ,SARS-CoV-2 ,CORONAVIRUSES ,DESERT plants ,COVID-19 ,MEDICINAL plants - Abstract
The emergence of superbugs and resistant pathogens poses a challenge in scientific and medical research as they threaten public health worldwide. Many herbal natural products currently used in therapies have been suggested to exert antimicrobial, antiviral and even virucidal activities against a vast majority of impervious pathogens. Rhazya stricta, a folk medicinal desert plant from Saudi Arabia was recently revealed to exhibit bactericidal activity against multidrug-resistant (MDR) microorganisms. The pandemic caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a threat to public health worldwide. Hence, we examined the antiviral activity of R. stricta against the virus. The R. stricta water extract was prepared at the traditional dose. The antagonistic effects of this extract against pathogens have been proven in previous studies, and those against SARS-CoV-2 were shown in the present study. Therefore, we explored the effects of the plant extracts and fractions against the virus for future drug development. All plant extracts showed antiviral effects against SARS-CoV-2 in the Vero E6 cell lines. Non-alkaloids showed the strongest effect against the virus, followed by weak base alkaloids and finally strong base alkaloids. A cytotoxicity assay was performed to explore the safest dose with the strongest antiviral effects. The non-alkaloid extract derived from R. stricta leaves is a promising antiviral candidate for the development of potential drugs with appropriate activity against COVID-19 and other life-threatening diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF